A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
PHASE1
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer i...
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
PHASE1
Multiple myeloma (MM) is a plasma cell disease characterized by the growth ...
Status
Active Not Recruiting
Location
University of Arkansas for Medical Sciences /ID# 243096
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
PHASE2
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer i...
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
PHASE1
Multiple myeloma (MM) is an incurable disease characterized by the growth o...
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
PHASE1
Multiple myeloma (MM) is a plasma cell disease characterized by the growth ...
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
PHASE1
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer i...
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
PHASE1
Immunoglobulin light chain (AL) amyloidosis is the most common form of syst...
Status
Recruiting
Location
Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
PHASE3
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer i...
Status
Active Not Recruiting
Location
University of Alabama at Birmingham - Main /ID# 261434